60 degrees pharmaceuticals to sponsor pilot study of tafenoquine for treatment of canine babesiosis

60 degrees pharma (nasdaq: sxtp) will sponsor a study using tafenoquine, an fda-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
SXTP Ratings Summary
SXTP Quant Ranking